http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 07:30:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html <p>Organon (NYSE: OGN) received U.S. Food and Drug Administration approval to expand the approved uses of TOFIDENCE (tocilizumab-bavi) injection to treat cytokine release syndrome and pediatric COVID-19 patients.</p><p>The FDA approved the supplemental Biologics License Application for TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), to include treatment of adults and pediatric patients 2 years and older with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The approval also covers hospitalized adult and pediatric patients aged 2 years and older with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.</p><p>TOFIDENCE http://www.streetinsider.com/Corporate+News/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html Wed, 10 Jun 2026 07:30:46 -0400 OGN http://www.streetinsider.com/FDA/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html <p>Organon (NYSE: OGN) received U.S. Food and Drug Administration approval to expand the approved uses of TOFIDENCE (tocilizumab-bavi) injection to treat cytokine release syndrome and pediatric COVID-19 patients.</p><p>The FDA approved the supplemental Biologics License Application for TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), to include treatment of adults and pediatric patients 2 years and older with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The approval also covers hospitalized adult and pediatric patients aged 2 years and older with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.</p><p>TOFIDENCE http://www.streetinsider.com/FDA/Organon+gets+FDA+approval+for+expanded+TOFIDENCE+uses/26626571.html Wed, 10 Jun 2026 07:30:46 -0400 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Press+Releases/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) approval of the supplemental Biologics License Application (sBLA) for TOFIDENCE® (tocilizumab-bavi) injection, for intravenous use, a biosimilar to ACTEMRA (tocilizumab). The approval expands TOFIDENCE indications to include treatment of: (1) adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) and (2) hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive http://www.streetinsider.com/Business+Wire/Organon+Secures+US+Food+and+Drug+Administration+Approval+Expanding+Indications+for+TOFIDENCE%C2%AE+%28tocilizumab-bavi%29+in+Cytokine+Release+Syndrome+%28CRS%29+and+Pediatric+COVID-19/26626555.html Wed, 10 Jun 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html <p class="bwalignc"> <i>New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio</i> </p> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. </p><p> Across 8 accepted abstracts, the data reflect Organon’s http://www.streetinsider.com/Press+Releases/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html Fri, 15 May 2026 07:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html <p class="bwalignc"> <i>New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio</i> </p> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. </p><p> Across 8 accepted abstracts, the data reflect Organon’s http://www.streetinsider.com/Press+Releases/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html Fri, 15 May 2026 07:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html <p class="bwalignc"> <i>New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio</i> </p> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. </p><p> Across 8 accepted abstracts, the data reflect Organon’s http://www.streetinsider.com/Business+Wire/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html Fri, 15 May 2026 07:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html <p class="bwalignc"> <i>New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio</i> </p> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. </p><p> Across 8 accepted abstracts, the data reflect Organon’s http://www.streetinsider.com/Business+Wire/Organon+to+Present+New+Research+on+Access+and+Value+at+ISPOR+2026/26499451.html Fri, 15 May 2026 07:30:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26452610.html si-local-file:///var/storage/secattach/20260507/26452610.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26452610.html Thu, 07 May 2026 16:01:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26452610.html si-local-file:///var/storage/secattach/20260507/26452610.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26452610.html Thu, 07 May 2026 16:01:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26450374.html si-local-file:///var/storage/secattach/20260507/26450374.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26450374.html Thu, 07 May 2026 10:02:00 -0400 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26450374.html si-local-file:///var/storage/secattach/20260507/26450374.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+May+06++Filed+by%3A+Holzbaur+Lynette/26450374.html Thu, 07 May 2026 10:02:00 -0400 O.50635033 OGN http://www.streetinsider.com/Earnings/Organon+%28OGN%29+Misses+Q1+EPS+by+12c/26400771.html <p>Organon (NYSE: OGN) reported Q1 EPS of $0.71, $0.12 worse than the analyst estimate of $0.83. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.52 billion.</p><p>For earnings history and earnings-related data on Organon (OGN) <a href="http://www.streetinsider.com/ec_earnings.php?q=OGN">click here</a>.</p> http://www.streetinsider.com/Earnings/Organon+%28OGN%29+Misses+Q1+EPS+by+12c/26400771.html Thu, 30 Apr 2026 07:44:32 -0400 OGN http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Press+Releases/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Business+Wire/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html <ul class="bwlistdisc"> <li> First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. </li> <li> First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. </li> <li> First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. </li> <li> On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) in an all-cash transaction (the “merger”). The merger is expected to close in early 2027, subject to customary closing http://www.streetinsider.com/Business+Wire/Organon+Reports+Results+for+the+First+Quarter+Ended+March+31%2C+2026/26400635.html Thu, 30 Apr 2026 07:30:00 -0400 A.06822034 O.20026344 O.50635033 OGN